Xavier Ding

Xavier Ding currently serves as the Clinical Strategy Manager at Abbott, where he plays a pivotal role in advancing the development and deployment of innovative rapid diagnostic tests (RDTs) for critical infectious diseases. Leveraging over a decade of experience in biomedical and clinical project management, Xavier brings a comprehensive understanding of the complexities involved in bringing life sciences solutions from concept to clinical application. His expertise spans areas such as in vitro diagnostics (IVD), immunology, and biotechnology, enabling him to design and implement robust clinical strategies that ensure the efficacy, safety, and regulatory compliance of Abbott’s diagnostic products.

In his current role, Xavier leads cross-functional teams to develop clinical trial protocols, optimize assay validation processes, and facilitate collaborations with global partners. His work is instrumental in ensuring that Abbott’s diagnostic solutions address unmet medical needs, particularly in low-income countries where access to reliable testing is critical for disease control and management. Xavier’s experience in malaria, drug discovery, and cell biology informs his approach to integrating innovative research with practical clinical applications. He is adept at building cohesion among diverse stakeholders, inspiring ownership, and fostering a culture of continuous improvement in clinical development.

Key projects under his leadership include the development of next-generation rapid tests for infectious diseases such as COVID-19 and other emerging pathogens. His strategic insights help streamline clinical pathways, accelerate product launch timelines, and ensure alignment with industry standards. With his extensive background in research, in vitro diagnostics, and global health, Xavier Ding is a vital contributor to Abbott’s mission to improve patient outcomes through innovative diagnostic solutions.